← back to Blog

Clinical Trials

Category Added in a WPeMatico Campaign

  • Public Health

    CONCLUSION: PlwD had a broad array of unmet healthcare needs, indicating primary healthcare provision improvement potentials. The results underscore the significance of early assessment of patient’s clinical characteristics and unmet needs as a basis for individualized gender-sensible intervention strategies.

    Read more →

  • Drug Development

    CONCLUSION: Benfotiamine reverses the changes of metabolites/lipids reflecting AD progression. Our ongoing NIH funded multicenter trial includes blood biomarkers of thiamine, amyloid, tau, inflammation, neurodegeneration, AGE, and extensive cognitive testing. A larger sample size is necessary to test whether metabolic biomarkers are useful for disease diagnosis, prognosis, and monitoring therapeutic efficacy. This research was partially…

    Read more →

  • Drug Development

    CONCLUSION: Preliminary findings from LatAm-FINGERS highlight the feasibility of conducting intervention trials within diverse populations. These findings underscore the importance of creating recruitment strategies that effectively engage underrepresented groups. This contributes significantly to global Alzheimer’s disease research efforts. The trial’s experience offers a valuable model for inclusive enrollment practices in Alzheimer’s disease and related dementia…

    Read more →

  • Drug Development

    CONCLUSION: AXS-05 demonstrated a substantial, rapid reduction in ADA vs controls after 5 weeks of treatment, increased time-to-relapse vs placebo, and was well-tolerated, supporting its development as a promising treatment option for ADA.

    Read more →

  • Drug Development

    CONCLUSION: A single bout of tVNS does not appear effective for improving cognition in individuals with MCI.

    Read more →

  • Drug Development

    CONCLUSION: Depending on correlations between prognostic scores and actual trial outcomes, a potential overall sample size reduction of 5-10% could be achieved using DT methodology (PROCOVA^(TM)) while maintaining statistical power, based on Δ CDR-SB and Δ ADAS-Cog 14 in the AWARE study. Sample size savings could enable shortening of the recruitment period and reduce the…

    Read more →

  • Drug Development

    CONCLUSION: Acute exercise decreases brain glucose metabolism in both cognitively healthy and impaired older adults. This effect tracks with the systemic lactate response. This supports the hypothesis that increased lactate may spare glucose and be a key brain fuel during exercise. Additional work to directly measure brain lactate metabolism following exercise and understand the role…

    Read more →

  • Technology and Dementia Preconference

    CONCLUSION: These promising results highlight the potential of biophoton therapy as a novel and safe intervention for Alzheimer’s disease. Further investigations are warranted to elucidate the underlying mechanisms. This clinical study represents a significant step forward in treating Alzheimer’s disease.

    Read more →

  • Dementia Care Research and Psychosocial Factors

    CONCLUSION: The preliminary findings indicate the intervention can lead to a sustained increase in knowledge and a shift in negative attitudes among CHWs over time. Further analysis are being carried out, including a qualitative assessment of the intervention, which will help improve the intervention to be applied in a randomized- controlled trial in the future.

    Read more →

  • The newborn behavioural observations (NBO) system embedded in routine postpartum care in at-risk families in Iceland: a randomised controlled trial

    CONCLUSION: Early home visits combining NBO with standard care enhance maternal confidence and the mother’s understanding of her infant. The small sample size makes it difficult to conclude whether repeated NBO sessions during the first month increase dimensions of maternal sensitivity in mother-infant interaction at 4 months postpartum.

    Read more →